German scientists have presented a dual modification strategy that combines CRISPR-Cas9 and CAR technology to enhance the efficacy of natural killer...

Dual CAR-T cells incorporating an IF/THEN logic-gated system show enhanced anti-tumour cytotoxicity and reduced off-tumour effects in mouse models....

Using CRISPR-Cas9 to knock out CD5, researchers have significantly improved the efficacy of adoptive T-cell therapies for both haematological and...

In this update, we highlight recent news on Poseida Therapeutics' fully allogeneic CAR-T candidate for multiple myeloma (P-BCMA-ALLO1), Intellia's and...

AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...